On DART figures for the third quarter of 2026, sales came to KRW 18.2 billion, up 1.8% from the same period a year earlier. Operating profit for the same period was KRW 1.94 billion, down 19.4%, and net income was KRW 1.2 billion, down 58.5%.
In a statement on November 17, 2026, the company presented cumulative third-quarter sales of KRW 51.3 billion and operating profit of KRW 5.0 billion, citing year-on-year gains of 5.0% and 33.9%, respectively. Cumulative operating margin was 9.7%, according to the company's disclosure.
The company attributed the cumulative improvement mainly to strong sales of Dr.Piel. For the first half of 2026, consolidated sales were KRW 33.2 billion, operating profit KRW 3.0 billion, and net income KRW 3.7 billion, up 6.8%, 131.2%, and 155.2% year on year.
The first-half operating margin rose from 4.2% to 9.2%, and first-half Dr.Piel sales reached KRW 21.0 billion, up 39%. Operating cash flow for the cumulative third quarter was KRW 5.5 billion, up 64.2% year on year. Shares opened the listing day on September 23, 2026 at as high as KRW 42,800 intraday.
As of 14:23 KST on November 18, 2026, the share price was KRW 5,430, down 1.45% from the previous close, with trading value of KRW 0.2 billion and market capitalization of KRW 54.4 billion.